Travelers can now feel even more confident to travel with new research from the US Department of Defense reinforcing that Travelan® is very effective in fending off travelers’ diarrhea – also known as the dreaded Montezuma’s Revenge. US Defense Force personnel are posted on assignments all around the globe, including developing countries where the risk of food and water contamination is high. One bout of travelers’ diarrhea can result in several days of discomfort or sometimes even weeks and weeks of severe illness. This can have a major impact on the assignment on hand, so a natural and simple treatment to reduce travelers’ diarrhea is a high priority objective.
The US Department of Defense (DoD) study was performed at an overseas laboratory located in Bangkok, Thailand and the results demonstrated that Travelan® was able to bind and was reactive to all 180 strains of bacteria tested.
Clinical trials show Travelan® confers protection of up to 90% against infection with the major strain of E.coli that causes travelers’ diarrhea. These trials also showed a significant reduction in abdominal cramps and stomach pain compared to those who did not receive Travelan.
This latest study from the US Department of Defense has demonstrated that Travelan may also be effective against Campylobacter, Shigella, and other pathogenic bacteria that may cause travelers’ diarrhoea. Shigella in particular is estimated to cause 80 –165 million cases of disease worldwide and is prevalent in South Asia and sub-Saharan Africa.
The latest DoD research provides extra confidence to business travelers and holiday makers who are seeking a simple way to reduce the chance of travelers’ diarrhea disrupting their travel experience.
Travelan’s active ingredient is Hyperimmune Bovine Colostrum Powder, a rich source of antibodies that bind to a nasty strain of E.coli called Enterotoxigenic E. coli (or ETEC) in the gastrointestinal tract, preventing them from attaching to the intestinal wall and reducing their ability to cause travelers’ diarrhea and its associated symptoms.
For further information on this study go to Immuron.com